Related Experiment Video
Updated: May 16, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
[Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status]
Tomohiro Nishi1, Yasuo Hamamoto, Junko Uemoto
1Kawasaki Comprehensive Care Center, Japan.
Abstract:
Because mFOLFOX6 has few contraindications, it is useful for poor performance status(PS)cases. However, in Japan, there are some reports that the dose is reduced easily. We retrospectively examined the safety/usefulness of the full dose mFOLFOX6(first-line)for advanced colon cancer patients with poor PS. Four of five cases had improved PS. The response rate was 60%. Grade 3/4 adverse events were infection, leukopenia, and neutropenia. Treatment-related deaths within 60 days of starting treatment were absent. Full-dose mFOLFOX6 for poor PS may be beneficial. However, we must consider the increased risk of adverse events.
Insights
Full-dose mFOLFOX6 chemotherapy is a potentially beneficial first-line treatment for advanced colon cancer patients with poor performance status (PS), showing a 60% response rate and improved PS in most cases. Careful monitoring for adverse events like neutropenia is essential.
Area of Science:
- Oncology
- Gastroenterology
- Clinical Pharmacology
Background:
- mFOLFOX6 chemotherapy is generally well-tolerated with few contraindications, making it a potential option for patients with poor performance status (PS).
- However, reports from Japan suggest frequent dose reductions of mFOLFOX6 in this patient population.
- This study investigates the safety and efficacy of full-dose mFOLFOX6 as a first-line treatment for advanced colon cancer in patients with poor PS.
Observation:
- Five patients with advanced colon cancer and poor PS received full-dose mFOLFOX6 as first-line therapy.
- Four out of five patients (80%) experienced an improvement in their performance status.
- The objective response rate was 60%.
Findings:
- Grade 3/4 adverse events observed included infection, leukopenia, and neutropenia.
- No treatment-related deaths occurred within 60 days of initiating treatment.
- Full-dose mFOLFOX6 demonstrated potential benefit in this cohort.
Implications:
- Full-dose mFOLFOX6 may be a viable and effective first-line treatment option for select advanced colon cancer patients with poor PS.
- Clinicians should be vigilant regarding the increased risk of severe adverse events, particularly neutropenia and infections.
- Further prospective studies are warranted to confirm these findings and establish optimal management strategies.
More Related Videos
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
